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provide lower bounds of prevalence estimates. Schizophrenia is
most prevalent in the low income and uninsured populations
than in the privately insured or Medicare populations.
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OBJECTIVE: To determine the incremental cost-effectiveness for
treating schizophrenia patients with olanzapine versus risperi-
done, quetiapine, amisulpride, or oral typical antipsychotics.
METHODS: European SOHO is a 3-year, prospective, outpa-
tient, observational study associated with antipsychotic treat-
ment in 10 European countries. Health care resource use and
clinical effectiveness data were collected at baseline, 3, 6, and 12
months. Clinical effectiveness was assessed using the Clinical
Global Impression (CGI) scale. UK health care costs were applied
to resource use data for the 10 countries. Pair-wise incremental
costs and effectiveness were estimated between olanzapine-
treated patients and patients treated with each of the other oral
antipsychotics. Incremental cost-effectiveness ratios (ICERs)
were presented as the additional cost per CGI unit gained.
RESULTS: A total of 10,972 patients were enrolled at baseline,
80% were eligible for analyses at 12 months. Pair-wise cost-
effectiveness comparisons, over 12 months, showed treatment
with olanzapine is more effective and less costly than quetiapine
and amisulpride. Treatment with olanzapine is more effective
compared to treatment with risperidone and marginally more
costly: £226 per patient over 12 months. The incremental cost-
effectiveness ratio was £1299 per additional decrease in CGI unit
gained. Treatment with olanzapine is more effective than oral
typical antipsychotics and marginal more costly: £849 per
patient over 12 months. The incremental cost-effectiveness ratio
for olanzapine versus oral typical treatment was £3166 per addi-
tional decrease in CGI unit gained. Treatment maintenance was
77% at 12 months with olanzapine, which was greater than that
for the other treatments. CONCLUSIONS: Olanzapine was cost
saving and more effective than treatment with quetiapine and
amisulpride. The cost-effectiveness of olanzapine compared to
respirodone and typicals depends on the value assigned to the
decrease in GCI unit gained. This needs to be considered,
however, in the context of treatment maintenance, which
favoured olanzapine.
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OBJECTIVE: The aim of this study was to estimate the cost-
effectiveness of treatment with ziprasidone vs. no-treatment
(placebo) for schizophrenia relapse prevention, in Spain.
METHODS: Treatment of schizophrenia was modeled over one
year, by means of a retrospective deterministic model, from the
National Health System (NHS) perspective (year 2005). The
primary outcome was the probability of relapse occurring within
a 52 weeks period of treatment with ziprasidone daily doses of
40–160mg vs. placebo. Data was obtained from a randomized,
double-blind, placebo-controlled clinical trial (N = 218 patients).
Antipsychotic cost, concomitant drugs to treat adverse events
(extrapiramidal symptoms, etc.) and medical costs associated to
adverse events were derived from the clinical trial results and
from a Spanish Health Cost database. The average cost of a
patient with acute psychosis relapse admitted to hospital in Spain
(€3421) was obtained from a retrospective analysis of medical
records of 200 patients admitted for acute psychosis in eight
Spanish hospitals (The Psychosp Study), previously published.
RESULTS: The probability of psychosis relapse was 0.77 with
placebo, and 0.43, 0.35, 0.36 and 0.38 for ziprasidone daily dose
of 40, 80, 160mg or weighted doses, respectively (p < 0.01 vs.
placebo in all cases). The number needed to treat (NNT) to avoid
1 relapse was 1.3 (95% CI 1.2–1.4), 2.3 (2.0–2.8), 2.9 (2.4–3.7),
2.8 (2.2–3.3), and 2.6 (2.2–3.3), respectively. The yearly average
incremental cost per relapse avoided was €186 for the weighted
dose of ziprasidone, and ranged from savings of €557 
(80mg/day) to incremental of €1015 (160mg/day), lower in all
cases than the cost of a relapse (€3421). CONCLUSIONS:
According to this evaluation, and compared with no treatment,
the psychosis relapse prevention with ziprasidone is cost-
effective from the Spanish NHS perspective.
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OBJECTIVES: Schizophrenia is a chronic, disabling and costly
disease which affects 2.2 million in US. No study has looked at
the patterns of drug therapy and cost of the disease in a previ-
ously insured population and how closely treatment guide-
lines are followed. Problem: Using data from Blue Shield of 
California, we determine drug utilization patterns and costs and
the relationship between these patterns and the American Psy-
chiatric Association treatment guidelines and total costs of schiz-
ophrenia treatment. METHODS: We used claims data from Blue
Shield of California during 2001–2004 to select all patients with
ICD-9 diagnoses of schizophrenia. Data was available for uti-
lization and costs of health care use, including mental health
carve-out care. We used a 6 month run-in and ending period in
case of incomplete claims data. Drug categories were typical and
atypical antipsychotics and mood stabilizers. Drug patterns were
monotherapy, combination therapy with and without mood sta-
bilizers, and several switch patterns. We used chi-square tests and
linear regression analysis to detect associations between utiliza-
tion patterns and costs. RESULTS: The 799 schizophrenia
patients had a mean age of 42.6 years (20.4–86.2) and 46.3%
were males. Total annual direct costs of treatment were
$6301/patient, 46% acute care services, and 45% prescription
drugs. The combination treatment group (2 antipsychotics/mood
stabilizer) as well as a monotherapy group (one switch antipsy-
chotic therapy) had the highest utilization and costs. Our regres-
sion showed higher total costs correlated with males and patients
with an average of 1.8 therapy switches while on otherwise single
stable antipsychotic therapy. Older patients and those on a mood
stabilizer contributed the least to cost. CONCLUSION: The
total annual costs of these insured schizophrenic patients
($6301) were substantially lower than the $25,940 reported for
Medicaid patients. Health care utilization and costs increased as
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treatment therapy became more complex according to the 
guidelines.
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OBJECTIVE: Atypical antipsychotic agents are considered the
ﬁrst-line treatment of schizophrenia. Aim of present study was
to identify factors affecting the cost of schizophrenia treatment
with atypical antipsychotic agents. METHODS: A retrospective
database study was conducted in three public hospitals in Hong
Kong. Patients initiated on atypical antipsychotic agents (amisul-
pride, olanzapine, quetiapine and risperidone) between March
2003 and September 2003 for treatment of schizophrenia for at
least three months was recruited. Patient medical records were
reviewed for up to 12 months before and after initiation date of
the antipsychotic agents to retrieve baseline demographic and
clinical factors and health care resource utilization for schizo-
phrenia. A multiple regression model was used to identify demo-
graphic, clinical factors and choice of atypical antipsychotic
agents with signiﬁcant association to health care resource uti-
lization. RESULTS: Eighty-two patients were included in the
analysis. Thirty-four (41%) patients were male and mean age
was 43 ± 14 years. The mean cost per patient per month was
USD 431 ± 914 (1USD = 7.8HKD). Three factors were associ-
ated with direct medical cost of health care resource utilized: 1).
History of drug abuse (RR = 1.26; 95% CI = 1.05–1.52); 2).
prior use of depot antipsychotic (RR = 1.22; 95% CI =
1.05–1.42); and 3). previous duration of hospitalization before
initiation of atypical antipsychotic therapy (RR = 1.00; 95% CI
= 1.00–1.01). CONCLUSION: History of drug abuse, prior use
of depot antipsychotic, previous duration of hospitalization
appeared to be inﬂuential to direct medical cost of atypical
antipsychotic treatment. The choice of antipsychotic agents did
not appear to affect the cost of treatment.
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OBJECTIVE: To determine the cost-effectiveness (measured
using an incremental cost-utility ratio) of treating schizophrenia
patients with olanzapine versus risperidone, quetiapine, amisul-
pride, or oral typical antipsychotics. METHODS: European
SOHO is a 3-year, prospective, outpatient, observational study
associated with antipsychotic treatment in 10 European coun-
tries. Health care resource use and quality of life data (EuroQol
EQ-5D and UK population utility values) were collected at base-
line, 3, 6, and 12 months. UK health care costs were applied to
the resource use data for the 10 countries. Pair-wise incremental
costs and utilities were estimated between olanzapine-treated
patients and patients treated with each of the other oral antipsy-
chotics. Utility increments were used to estimate quality-adjusted
life-years (QALYs) gained. Incremental cost-utility ratios were
expressed as the additional cost per QALY gained. Bootstrap
replications provided an estimate of uncertainty. RESULTS: A
total of 10,972 patients were enrolled at baseline, 80% were eli-
gible for analyses at 12 months. Treatment with olanzapine is
more effective and less costly than quetiapine and amisulpride.
Treatment with olanzapine is more effective compared to treat-
ment with risperidone. The incremental cost is marginal. The
incremental cost-utility ratio was £5156 per additional QALY
gained. The bootstrap replications for the above comparisons
showed 100% of the replications falling below a £30,000 per
QALY threshold. Treatment with olanzapine is more effective
compared to treatment with oral typical antipsychotics. The
additional cost is marginal. The incremental cost-utility ratio 
for olanzapine versus oral typical treatment was £15,696 per
additional QALY gained. The bootstrap replications showed
97% of the replications below a $30,000 per QALY threshold.
CONCLUSIONS: Among SOHO patients, if a funding thresh-
old of £30,000 per QALY gained is assumed, olanzapine has a
high probability of being the most cost-effective treatment 
compared with atypical and oral typical antipsychotic 
medications.
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OBJECTIVES: To determine current neuroleptic drug utilization
patterns of ambulatory care schizophrenic patients in Germany.
METHODS: Analysis of routine prescription data for the years
2003/2004 of patients insured with the Techniker Krankenkasse
sickness fund (covering approximately 6-million insured persons
distributed across all German states) with a hospital diagnosis of
schizophrenia F20 (ICD-10) in 2003. RESULTS: In 2004, 3397
patients with schizophrenia received 28,434 prescriptions for
neuroleptic drugs. In total, 33.1% of prescriptions were for
typical, 66.9% for atypical neuroleptics. In total, 51.2% of
typical neuroleptics prescribed were high-potency, 48.8% low-
potency drugs. Olanzapine was the most frequently prescribed
atypical (26.5%), followed by Clozapine (21.1%), Risperidone
(19.2%), Quetiapine (14.5%), Amisulpride (11.9%), Ziprasi-
done (6.2%), and Zotepine (0.6%). Analysing prescriptions on
an individual patient level gave a similar picture. During a 12
month-period after their ﬁrst hospital stay in 2003, 1490 patients
(43.9%) were treated only with atypical neuroleptics, 555
patients (17.2%) were treated with an atypical plus a low-
potency typical neuroleptic as adjuvant therapy. In total, 280
patients (8.7%) received typical neuroleptics only and 245
patients (7.6%) were prescribed both high-potency typical and
atypical neuroleptics. The remaining patients received no ambu-
latory prescriptions for neuroleptics. Some of them may have
received drugs from hospital pharmacies which are not recorded
in the ambulatory prescription database. CONCLUSIONS:
Reaching 61% in 2003/2004, the proportion of schizophrenic
patients receiving atypical neuroleptic drugs as their main med-
ication in our study population is much higher than previously
thought and in the range of other western European countries.
However, the share of Clozapine is also much higher than in
most countries. Although this non-random sample is not repre-
sentative of the German population, major differences in pre-
scribing behaviour depending on a patient’s sickness fund are
